INOVIQ shows 94% accuracy for its ovarian cancer diagnostic test

Biotech company INOVIQ Limited (ASX:IIQ) has yielded positive results from an independent patient assessment of its blood test to screen for ovarian cancer, with more than 94% accuracy.

The assessment was built around patient validation of the EXO-OC blood test, considering factors such as its biomarkers and diagnostic performance

The study isolated exosomes from more than 500 blood samples through the use of INOVIQ’s EXO-NET – a tool used for biomarker discovery and diagnostic development – on a high-throughput, fully automated robotic platform.

Exosome ovarian cancer biomarkers were measured using targeted mass spectrometry.

The latter part was conducted by The University of Queensland’s (UQ) Centre for Extracellular Vesicle Nanomedicine, and the biomarkers had already been identified during the OC97 study.

All targeted biomarkers were identified in ovarian cancer samples, and their diagnostic performance was confirmed using ROC curve analysis and multivariate modelling.

Additional cancer biomarkers were identified through the EXO-NET isolation of exosomes.

Director of the UQ Centre for Extracellular Vesicle Nanomedicine Professor Carlos Salomon
Gallo said the results held various impressive aspects.

“This study demonstrated that the EXO-OC test identified ovarian cancer across all stages
with an overall accuracy of over 94%,” he said.

“Notably, the EXO-OC test is particularly accurate in identifying early stages of ovarian cancer, achieving a sensitivity of more than 90% and specificity of 96% for stage I, where women have a five-year survival rate of over 90%.”

INOVIQ has been trading at 46.5 cents.

Join the discussion: See what HotCopper users are saying about INOVIQ and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.